Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 108

1.

Clinical predictors of response to olanzapine or risperidone during acute episode of schizophrenia.

Brousse G, Meary A, Blanc O, Lançon C, Llorca PM, Leboyer M.

Psychiatry Res. 2010 Aug 30;179(1):12-8. doi: 10.1016/j.psychres.2009.03.003. Epub 2010 May 15.

PMID:
20472305
2.

Switching to olanzapine after unsuccessful treatment with risperidone during the first episode of schizophrenia: an open-label trial.

Takahashi H, Kamata M, Yoshida K, Ishigooka J, Higuchi H.

J Clin Psychiatry. 2006 Oct;67(10):1577-82.

PMID:
17107250
3.

A practical clinical trial comparing haloperidol, risperidone, and olanzapine for the acute treatment of first-episode nonaffective psychosis.

Crespo-Facorro B, Pérez-Iglesias R, Ramirez-Bonilla M, Martínez-García O, Llorca J, Luis Vázquez-Barquero J.

J Clin Psychiatry. 2006 Oct;67(10):1511-21.

PMID:
17107241
4.

[Antipsychotics in bipolar disorders].

Vacheron-Trystram MN, Braitman A, Cheref S, Auffray L.

Encephale. 2004 Sep-Oct;30(5):417-24. Review. French.

PMID:
15627046
5.

[Cost-effectiveness analysis of schizophrenic patient care settings: impact of an atypical antipsychotic under long-acting injection formulation].

Llorca PM, Miadi-Fargier H, Lançon C, Jasso Mosqueda G, Casadebaig F, Philippe A, Guillon P, Mehnert A, Omnès LF, Chicoye A, Durand-Zaleski I.

Encephale. 2005 Mar-Apr;31(2):235-46. Review. French.

PMID:
15959450
6.

Predictors of acute treatment response in patients with a first episode of non-affective psychosis: sociodemographics, premorbid and clinical variables.

Crespo-Facorro B, Pelayo-Terán JM, Pérez-Iglesias R, Ramírez-Bonilla M, Martínez-García O, Pardo-García G, Vázquez-Barquero JL.

J Psychiatr Res. 2007 Oct;41(8):659-66. Epub 2006 Jun 23.

PMID:
16797591
7.

Evidence for the effectiveness of olanzapine among patients nonresponsive and/or intolerant to risperidone.

Dossenbach MR, Kratky P, Schneidman M, Grundy SL, Metcalfe S, Tollefson GD, Belmaker RH.

J Clin Psychiatry. 2001;62 Suppl 2:28-34.

8.

[Prescription of olanzapine in children and adolescent psychiatric patients].

Frémaux T, Reymann JM, Chevreuil C, Bentué-Ferrer D.

Encephale. 2007 Mar-Apr;33(2):188-96. Review. French.

PMID:
17675914
9.

A randomized, 1-year follow-up study of olanzapine and risperidone in the treatment of negative symptoms in outpatients with schizophrenia.

Alvarez E, Ciudad A, Olivares JM, Bousoño M, Gómez JC.

J Clin Psychopharmacol. 2006 Jun;26(3):238-49.

PMID:
16702888
10.
11.

How effective is it to sequentially switch among Olanzapine, Quetiapine and Risperidone?--A randomized, open-label study of algorithm-based antipsychotic treatment to patients with symptomatic schizophrenia in the real-world clinical setting.

Suzuki T, Uchida H, Watanabe K, Nomura K, Takeuchi H, Tomita M, Tsunoda K, Nio S, Den R, Manki H, Tanabe A, Yagi G, Kashima H.

Psychopharmacology (Berl). 2007 Dec;195(2):285-95. Epub 2007 Aug 14.

PMID:
17701027
12.

Belgian Schizophrenia Outcome Survey - results of a 2-year naturalistic study in patients stabilised on monotherapy with olanzapine, risperidone or haloperidol.

Peuskens J, Gillain B, De Graeve D, Van Vleymen B, Albert A.

Eur Psychiatry. 2009 Apr;24(3):154-63. doi: 10.1016/j.eurpsy.2008.11.002. Epub 2008 Dec 31.

PMID:
19118983
13.

An algorithm-based approach to first-episode schizophrenia: response rates over 3 prospective antipsychotic trials with a retrospective data analysis.

Agid O, Arenovich T, Sajeev G, Zipursky RB, Kapur S, Foussias G, Remington G.

J Clin Psychiatry. 2011 Nov;72(11):1439-44. doi: 10.4088/JCP.09m05785yel. Epub 2011 Mar 8.

PMID:
21457676
14.

Factors influencing acute weight change in patients with schizophrenia treated with olanzapine, haloperidol, or risperidone.

Basson BR, Kinon BJ, Taylor CC, Szymanski KA, Gilmore JA, Tollefson GD.

J Clin Psychiatry. 2001 Apr;62(4):231-8.

PMID:
11379836
15.

Safety and effectiveness of olanzapine versus conventional antipsychotics in the acute treatment of first-episode schizophrenic inpatients.

Bobes J, Gibert J, Ciudad A, Alvarez E, Cañas F, Carrasco JL, Gascón J, Gómez JC, Gutiérrez M.

Prog Neuropsychopharmacol Biol Psychiatry. 2003 May;27(3):473-81.

PMID:
12691783
16.

Effectiveness of antipsychotic treatments for schizophrenia: interim 6-month analysis from a prospective observational study (IC-SOHO) comparing olanzapine, quetiapine, risperidone, and haloperidol.

Dossenbach M, Erol A, el Mahfoud Kessaci M, Shaheen MO, Sunbol MM, Boland J, Hodge A, O'Halloran RA, Bitter I; IC-SOHO Study Group.

J Clin Psychiatry. 2004 Mar;65(3):312-21.

PMID:
15096069
17.

Meta-analysis comparing newer antipsychotic drugs for the treatment of schizophrenia: evaluating the indirect approach.

Sauriol L, Laporta M, Edwardes MD, Deslandes M, Ricard N, Suissa S.

Clin Ther. 2001 Jun;23(6):942-56.

PMID:
11440294
18.

Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment.

McEvoy JP, Lieberman JA, Stroup TS, Davis SM, Meltzer HY, Rosenheck RA, Swartz MS, Perkins DO, Keefe RS, Davis CE, Severe J, Hsiao JK; CATIE Investigators.

Am J Psychiatry. 2006 Apr;163(4):600-10.

PMID:
16585434
19.

Efficacy of risperidone versus olanzapine in patients with schizophrenia previously on chronic conventional antipsychotic therapy: a switch study.

Wang X, Savage R, Borisov A, Rosenberg J, Woolwine B, Tucker M, May R, Feldman J, Nemeroff CB, Miller AH.

J Psychiatr Res. 2006 Oct;40(7):669-76. Epub 2006 Jun 9.

PMID:
16762371
20.

Olanzapine versus placebo in adolescents with schizophrenia: a 6-week, randomized, double-blind, placebo-controlled trial.

Kryzhanovskaya L, Schulz SC, McDougle C, Frazier J, Dittmann R, Robertson-Plouch C, Bauer T, Xu W, Wang W, Carlson J, Tohen M.

J Am Acad Child Adolesc Psychiatry. 2009 Jan;48(1):60-70. doi: 10.1097/CHI.0b013e3181900404.

PMID:
19057413
Items per page

Supplemental Content

Write to the Help Desk